Consilient Health form new partnership with Italfarmaco for Blissel®

On 10th November 2022, Consilient Health Ltd entered a distribution and promotional partnership with Italfarmaco Group for Blissel^®, its vaginal gel for the UK territory.

Luke Crosbie, CEO, Consilient Health said “this represents a significant strategic addition to Consilient Health’s already successful Women’s Health branded product portfolio for the UK”. He also noted that “….we are delighted and excited to be in a continuing partnership with Italfarmaco to supply the UK market with Blissel^®.”

“We are proud of this new agreement with Consilient Health for our product Blissel^® as it represents both an established therapeutic opportunity for patients’ needs as well as an interesting business opportunity for our organisation” – said Carlos Barallobre, CEO of Italfarmaco Group. Blissel^® will be made available via Consilient Health through the UK supply chain for wholesalers by February 2023.

Consilient Health Ltd is a pharmaceutical company with a rich heritage of commercialising products in areas such as women’s health, endocrinology, bone health and urology. Consilient Health was established in 2005.

Italfarmaco Group is a specialty pharmaceutical company with global revenues of about 1.1 billion EUR, engaged in the discovery, development, manufacturing and marketing of branded prescription and non-prescription products in more than 60 countries on 5 continents. Italfarmaco Group’s research and development expertise is best demonstrated through its HDAC inhibitor development programs, addressing new therapeutic treatments of specialty and rare diseases. Through both marketed drugs and compounds in development, Italfarmaco Group is dedicated to serving patients whose needs remain largely unmet.

For more information, please contact info@consilienthealth.com